


Cardiovascular Pharmacology

- **Antiarrhythmic drugs**
- **Drugs in heart failure**
- **Antihypertensive drugs**
- **Antianginal drugs**
- **Antihyperlipidemic drugs**

Antiarrhythmic Drugs


Prof. Abdulrahman Almotrefi



Learning objectives

By the end of this lecture, students should be able to:

- **Understand** definition of arrhythmias and their different types
- **describe** different classes of Antiarrhythmic drugs and their mechanism of action
- **understand** their pharmacological actions, clinical uses, adverse effects and their interactions with other drugs.








Cardiac Conduction System

CARDIAC CONDUCTION SYSTEM

- S.A. node**
- Inter-nodal pathways**
- A.V. node**
- Bundle of His and branches**
- Purkinje fibers**


Electrocardiogram (ECG)




Electrical and Mechanical Events

CARDIAC ACTION POTENTIAL


Skeletal action potential:



Cardiac action potential:




Fast-Response Action Potential (e.g., ventricular myocyte)




CARDIAC ACTION POTENTIAL

Non-pacemaker (ventricular muscle)




CARDIAC ACTION POTENTIAL

Pacemaker (SA node)



Difference between pacemaker and non-pacemaker action potential




WHAT IS ARRHYTHMIA?

An **abnormality** in the :

■ rate high= tachycardia


low = bradycardia

Normal Sinus Rhythm



| Heart Rate | Rhythm | P Wave | PR interval (in seconds) | QRS (in seconds) |
|------------|---------|----------------------------|--------------------------|------------------|
| 60-100 bpm | Regular | Before each QRS, identical | .12 to .20 | <.12 |

Sinus Tachycardia



**Heart
Rate**

Rhythm

P Wave

**PR interval
(in seconds)**

**QRS
(in seconds)**

> 100 bpm


Regular

**Before each
QRS, identical**

.12 to .20

<.12

Sinus Bradycardia




| Heart Rate | Rhythm | P Wave | PR interval (in seconds) | QRS (in seconds) |
|------------|---------|----------------------------|--------------------------|------------------|
| < 60 bpm | Regular | Before each QRS, identical | .12 to .20 | <.12 |

WHAT IS ARRHYTHMIA?


An **abnormality** in the :

- rate high= tachycardia
low = bradycardia
- regularity Extrasystoles
(PAC, PVC)

Multifocal PVC's: more than one shape



Atrial Fibrillation



| Heart Rate | Rhythm | P Wave | PR interval (in seconds) | QRS (in seconds) |
|------------------------------------|-----------|-------------------------------|--------------------------|------------------|
| A: 350-650 bpm V: Slow to rapid | Irregular | Fibrillatory (fine to coarse) | N/A | <.12 |

Disturbances in conduction

1st degree AV Block



2nd degree AV Block
Wenkebach/Mobitz I



2nd degree AV Block
Mobitz II



3rd degree AV Block



Therapeutic use of antiarrhythmic drugs

The ultimate goal of therapy



Restore normal rhythm & conduction



**Maintenance of
normal rhythm**



**Prevention of more
serious arrhythmias**

How antiarrhythmic drugs produce these effects?

- **Slow conduction velocity**
- **Altering the excitability of cardiac cells by prolonging the effective refractory period**
- **Suppressing ectopic pacemaker activity by inhibiting phase 4 slow depolarization**

**CLASSIFICATION
OF
ANTIARRHYTHMIC DRUGS**

Vaughn Williams classification

CLASS I

**Na⁺ channel blockers
(membrane stabilizing drugs)**

CLASS II:

β- adrenoceptor blockers

CLASS III:

Drugs that prolong action potential duration

CLASS IV:

Calcium channel blockers

CLASS I



Drugs that block the influx of **Na ions** through **Na channels**



1- decrease the rate of rise of rapid depolarization (Phase 0)

2- decrease phase 4 slow depolarization (suppress pacemaker activity)

(membrane stabilizing effect)



CLASS I

- **Sub classified according to their effect on action potential duration :**
 - **la** : prolong action potential duration
 - **lb** : shorten action potential duration
 - **lc** : no effect on action potential duration

CLASS I a


Ia : prolong action potential duration

e.g.

Quinidine

Procainamide

Class IA drugs slow Phase 0 depolarization, prolong action potential, and slow conduction.



CLASS I a QUINIDINE

Other pharmacological actions :

1- Anticholinergic effect:



Increase conduction through the A.V. node

(risk of ventricular tachycardia)

2- α -adrenergic blocking effect:



may cause vasodilatation & reflex sinus tachycardia

(seen more after I.V. dose)

3- ECG changes:

- prolongs P-R and Q-T interval
- widens QRS complex

CLASS I a

QUINIDINE


Therapeutic uses:

- **atrial flutter & fibrillation**
- **maintaining sinus rhythm after cardioversion**

CLASS Ia QUINIDINE

Adverse effects :

quinidine syncope: episodes of fainting due to **torsades de pointes** (twisting of the spikes) developing at therapeutic plasma levels




Torsades de pointes

- may terminate spontaneously or lead to



fatal ventricular fibrillation

Ventricular Fibrillation



| Heart Rate | Rhythm | P Wave | PR interval (in seconds) | QRS (in seconds) |
|------------|---------------------|--------|--------------------------|-----------------------|
| 300-600 | Extremely irregular | Absent | N/A | Fibrillatory baseline |

CLASS I a
QUINIDINE

Adverse effects :

❖ **Anticholinergic adverse effects:**

- **Dry mouth**
- **Blurred vision**
- **Urinary retention**
- **constipation**

❖ **Hypotension**

- **due to depressing contractility & vasodilatation**

GIVEN ORALLY (Rarely given I.V.)

CLASS I a

PROCAINAMIDE

Similar to quinidine except :

1- less toxic on the heart...

can be given I.V.

2- more effective in ventricular than in

atrial arrhythmias

3 - No anticholinergic or α -blocking actions

CLASS I a
PROCAINAMIDE

Adverse effects:

- In long term therapy it causes reversible
lupus erythematosus-like syndrome
- Hypotension
- Torsades de pointes
- Hallucination & psychosis

CLASS I b


- **Shorten action potential duration**

e.g.

Lidocaine

Mexiletine

Class IB drugs shorten Phase 3 repolarization and decrease the duration of the action potential.



CLASS Ib
LIDOCAINE

Therapeutic uses :

treatment of **emergency** ventricular arrhythmias

e.g. :

- 1 - during surgery
 - 2 - following acute myocardial infarction
- **NOT** effective in atrial arrhythmias
 - **NOT** effective orally (3% bioavailability)
 - given I.V. bolus or slow infusion
 - $t_{1/2} = 2$ hours

CLASS Ib
LIDOCAINE

Adverse effects:

- ❑ hypotension
- ❑ similar to other local anesthetics,
causes CNS adverse effects such as:
 - paresthesia
 - tremor
 - dysarthria (slurred speech)
 - tinnitus
 - confusion
 - **convulsions**

CLASS Ib
MEXILETINE

- EFFECTIVE ORALLY

Therapeutic uses :

- 1- ventricular arrhythmia**
- 2- digitalis-induced arrhythmias**

$t_{1/2} = 10$ hours

ADVERSE EFFECTS :

- 1- nausea , vomiting**
- 2- tremor , drowsiness, diplopia**
- 3- arrhythmias & hypotension**


CLASS Ic

- have no effect on action potential duration

e.g.

Flecainide

Class IC drugs markedly slow Phase 0 depolarization.




CLASS Ic
FLECAINIDE

Therapeutic uses :

- **supraventricular arrhythmias**
- **Wolff-Parkinson-White syndrome**
- **very effective in ventricular arrhythmias, but very high risk of **proarrhythmia****
- **should be reserved for resistant arrhythmias**

Wolff-Parkinson-White syndrome

- Pre-excitation of the ventricles due to an accessory pathway known as the Bundle of Kent.



CLASS Ic
FLECAINIDE

Adverse effects:

1- proarrhythmia

2- CNS :

**dizziness, tremor, blurred vision,
abnormal taste sensations, paraesthesia**

3- heart failure due to -ve inotropic effect

CLASS II DRUGS

β- ADRENOCEPTOR BLOCKERS

pharmacological actions :

block β_1 - receptors in the heart



reduce the sympathetic effect on the heart



- 1 - decrease automaticity of S.A. node and ectopic pacemakers**
- 2 - prolong refractory period (slow conduction) of the A.V node**

CLASS II DRUGS

β - ADRENOCEPTOR BLOCKERS

Therapeutic uses :

1- atrial arrhythmias associated with emotion:

- e.g. :**
- after exercise**
 - thyrotoxicosis**

2- WPW

3- digitalis-induced arrhythmias

CLASS II DRUGS

β - ADRENOCEPTOR BLOCKERS

Therapeutic uses :

Esmolol :

- very short acting (half-life = 9 min.)
- given I.V. for rapid control of ventricular rate in patients with atrial flutter or fibrillation

Propranolol, Atenolol, Metoprolol :

- used in patients who had myocardial infarction to reduce incidence of sudden death due to ventricular arrhythmias

CLASS III DRUGS

- **Prolong the action potential duration and refractory period**
- **Prolong phase 3 repolarization**

Class III drugs prolong
Phase 3 repolarization,
without altering Phase 0.



CLASS III DRUGS

AMIODARONE

pharmacological actions :

- prolongs action potential duration and therefore prolongs refractory period (**Main effect**)
- additional class Ia, II & IV effects
- vasodilating effects
(due to its α - & β -adrenoceptor blocking effects and its calcium channel blocking effects)

CLASS III DRUGS

AMIODARONE

Therapeutic uses :

- 1- main use : serious resistant ventricular arrhythmias
- 2- maintenance of sinus rhythm after cardioversion
- 3- resistant supraventricular arrhythmias (e.g. WPW)

CLASS III DRUGS

AMIODARONE

Adverse effects:

- exacerbation of ventricular arrhythmias
(with high dose)
- bradycardia and heart failure
- pulmonary fibrosis
- hyper- or hypothyroidism
- photodermatitis & skin deposits
(patients should avoid exposure to the sun)

CLASS III DRUGS

AMIODARONE

Adverse effects:

- Neurological:
 - e.g. tremors and peripheral neuropathy
- nausea, vomiting and constipation
- corneal micro deposits
- hepatocellular necrosis

CLASS III DRUGS

AMIODARONE

Pharmacokinetics:

- extremely long $t_{1/2} = 13 - 103 \text{ DAYS}$
- metabolized by CYP3A4 and CYP2C8 to its major
active metabolite: **N-desethylamiodarone**
- eliminated primarily by hepatic metabolism
- cross placenta and appear in breast milk

CLASS III DRUGS

AMIODARONE

Drug Interactions:

1 - Co-administration of amiodarone with drugs that prolong the QT interval increases the risk of Torsades de Points

e.g. :

macrolide antibiotics (Clarithromycin, Erythromycin)

azole antifungals (Ketoconazole)

CLASS III DRUGS

AMIODARONE

Drug Interactions:

- 2- Drugs (or substances) that **inhibit** these enzymes
Cause increase in serum concentration of amiodarone
e.g. : Loratadine, Ritonavir , Trazodone
Cimetidine, Grapefruit juice

- 3- Drugs that induce these enzymes
Cause decrease in serum concentration of amiodarone
e.g. : Rifampin

PURE CLASS III

Ibutilide

- **Given by rapid I.V. infusion**
- **Used for the acute conversion of atrial flutter or fibrillation to normal sinus rhythm**
- **Causes QT interval prolongation**
(may cause torsades de pointes)

Class 1V

calcium channel blockers

Verapamil, Diltiazem

- **main site of action is A.V.N & S.A.N**
cause:
 - **slowing of conduction**
 - **prolongation of effective refractory period**

Class 1V calcium channel blockers

Therapeutic uses :

- 1- atrial arrhythmias
- 2- re-entry supraventricular arrhythmias
e.g. WPW
- 3- NOT effective in ventricular arrhythmias

ADENOSINE

Mechanism of action :

- inhibits cAMP by binding to adenosine **A1** receptors causing the following actions:

1 - opening of potassium channels


(hyperpolarization)

2 - decreasing conduction velocity mainly at AV node

(negative dromotropic effect)

3- inhibiting phase 4 pacemaker action potential at SA node

(negative chronotropic effect)



ADENOSINE

Therapeutic uses :

- drug of choice for acute management of paroxysmal supraventricular tachycardia
 - preferred over verapamil
(safer and does not depress contractility)
- half-life = less than 10 sec**

ADENOSINE

Adverse effects:

- flushing in about 20% of patients
- shortness of breath and chest burning in 10% of patients (due to bronchospasm)
- brief AV block (contraindicated in heart block)

New Antiarrhythmic Drugs

Dronedarone

- **a noniodinated congener of amiodarone**
- **has antiarrhythmic properties belonging to all four classes**
- **Used for maintenance of sinus rhythm following cardioversion in patients with atrial fibrillation**

New Antiarrhythmic Drugs

Dronedarone

WARNINGS

- should **not** be used in patients with severe (class IV) heart failure. Risk of death may be increased in these patients.
- should **not** be used in patients with permanent atrial fibrillation. Risk of death and stroke, may be increased in these patients.

BRADYARRHYTHMIAS


ATROPINE

- used in sinus bradycardia after myocardial infarction and in heart block
- in emergency heart block **isoprenaline** may be combined with atropine (**caution**)

NONPHARMACOLOGIC THERAPY OF ARRHYTHMIAS

Implantable Cardiac Defibrillator (ICD)

- can automatically detect and treat fatal arrhythmias such as ventricular fibrillation



Thank you

